Navigation Links
MedImmune's Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
Date:8/23/2007

GAITHERSBURG, Md., Aug. 23 /PRNewswire/ -- MedImmune, Inc. today announced that in a Phase 3 study, motavizumab was shown to reduce hospitalizations due to respiratory syncytial virus (RSV) by 83 percent as compared to placebo (8.3 percent in placebo arm vs. 1.4 percent in motavizumab; p<0.001), as the trial's primary endpoint. In addition, the trial showed a 71-percent reduction in the incidence of RSV-specific lower respiratory infections (LRIs) requiring outpatient management (9.5 percent in placebo group and 2.8 percent in the motavizumab group; p<0.001), which was a secondary endpoint.

Motavizumab is an investigational monoclonal antibody (MAb) being evaluated for its potential to prevent serious disease caused by RSV in high-risk pediatric patients. This Phase 3 trial involved 1,410 full-term infants less than six months of age in two Native American populations. In previous medical studies these populations were shown to have high rates of hospitalization due to RSV.

The randomized (2:1), double-blind study was designed to compare monthly intramuscular injections of motavizumab against placebo. After an interim analysis conducted by an independent data safety monitoring committee, the study was unblinded early due to statistical evidence demonstrating that motavizumab reduced RSV hospitalizations and LRIs requiring outpatient medical management within this population. Kate O'Brien, M.D., associate professor at the Center for American Indian Health, Johns Hopkins Bloomberg School of Public Health, served as the study's principal investigator.

"We are pleased with the results of this study which support the positive results seen in our Phase 3 pivotal trial comparing motavizumab and Synagis(R) (palivizumab) that were previously reported at the Pediatric Academic Societies meeting in May 2007," said Genevieve Losonsky, M.D., vice president, clinical development, infectious disease, MedImmune.

Motavizumab was well tolerated in these
'/>"/>

SOURCE MedImmune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
7. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
8. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
9. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat
10. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
11. Data Suggest Cymbalta Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... SAN FRANCISCO , Oct. 22, 2014 ... fitness and health trackers for themselves and their kids, ... Mom 2014 Report: Health & Fitness Go Mobile for ... Mom® Insights Series. BabyCenter, the number 1 pregnancy and ... which found that 55 percent of moms surveyed say ...
(Date:10/22/2014)... -- A new report by Allied Market ... End user, Application and Geography) - Size, Share, Global ... Segmentation and Forecast, 2013 - 2020", considers commercial aspects ... trends tracked, it is anticipated that the market is ... registering a CAGR of 6.2% from 2014 to 2020. ...
(Date:10/22/2014)... 2014 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral ... results from its Phase IIa clinical trial of ... treat type 1 diabetes. The trial was conducted in ... a U.S. Food and Drug Administration (FDA) Investigational ...
Breaking Medicine Technology:BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 3BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 4Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4
... GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta-based, biopharmaceutical ... Immunodeficiency Virus (HIV) infections, today announced its financial results and ... 30, 2011. GeoVax reported a net loss of ... 30, 2011, compared to $933,089 ($0.06 per share) for the ...
... Spherix Incorporated (NASDAQ: SPEX ) ... metabolic syndrome and atherosclerosis, and providers of technical and ... companies – today reported financial results for the three ... Recent and Upcoming Highlights ...
Cached Medicine Technology:GeoVax Labs, Inc. Announces Second Quarter Financial Results 2GeoVax Labs, Inc. Announces Second Quarter Financial Results 3GeoVax Labs, Inc. Announces Second Quarter Financial Results 4Spherix Announces Second Quarter Financial Results 2Spherix Announces Second Quarter Financial Results 3Spherix Announces Second Quarter Financial Results 4Spherix Announces Second Quarter Financial Results 5Spherix Announces Second Quarter Financial Results 6Spherix Announces Second Quarter Financial Results 7
(Date:10/25/2014)... News) -- Interrupting blood supply to an arm or a ... with the surgery, according to a new study. ... to the heart to be able to operate on it. ... its ability to produce energy because it doesn,t get oxygen. ... muscle, such as an arm or a leg, the body ...
(Date:10/25/2014)... News) -- Current osteoporosis screening guidelines and tools ... risk for osteoporosis-related fractures, a new study says. ... need tools that help us accurately predict who ... can target these at-risk people for preventive measures," ... in the division of general internal medicine and ...
(Date:10/22/2014)... On October 22, CBS will air ... diseases both fictional and real. The Charles E ... committed to advocacy and philanthropy in the battle against ... opportunity to impart truth and clarity about this misunderstood ... many misconceptions about Morgellons Disease (MD) and ...
(Date:10/22/2014)... -- The United States is now mandating that ... West Africa land at one of five airports ... virus. In a statement released Tuesday, Homeland ... of air passengers from Guinea, Liberia and Sierra ... airports -- New York City,s Kennedy International Airport, ...
(Date:10/22/2014)... During the Western United States’ worst ... dangerously low, Southern Oregon’s water is proving resistant to ... lowest mountain snow pack on record in 2014, remain ... autumn.* That was the observation of journalist-hikers Art Bernstein ... Southern Oregon,” during an interview with water advocate Sharon ...
Breaking Medicine News(10 mins):Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Osteoporosis Screening Guidelines May Miss Younger Women at Risk 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4
... One year after a person is diagnosed with rheumatoid arthritis ... attack compared to people without the disease, a new study ... diagnosed with rheumatoid arthritis, a chronic autoimmune disease marked by ... than 37,000 people without the disease. The study was conducted ...
... from a large European study suggest that poorly educated people ... heart failure than the better educated, even after differences in ... online today (Thursday 9 December) in the European Heart ... as long as 31 years (range 0-31 years, average follow-up ...
... LOS ANGELES (December 8, 2010) Jeffrey S. Upperman, ... Angeles, has co-authored a call to action for filling a ... oversight to establish the framework for a pediatric applied trauma ... simultaneously in the Journal of Pediatric Surgery and ...
... kid trying to join in and be one of the ... feel included, be accepted and valued particularly by their ... children with disabilities around inclusion in physical activities during free ... physical activity expert, in the Faculty of Physical Education and ...
... HealthDay Reporter , WEDNESDAY, Dec. 8 (HealthDay News) -- Sudden infant ... a mysterious and terrifying killer of newborns. But medical researchers ... to die of SIDS, an advance that could save hundreds ... die of SIDS tend to have significantly lower amounts of serotonin ...
... , Prostate cancer is the most common type of cancer ... inaccurate and unpleasant. Researchers at Eindhoven University of Technology (TU/e), ... that can accurately identify tumors. The technology is based on ... tumors are. This can lead to better and more appropriate ...
Cached Medicine News:Health News:Study Suggests Rheumatoid Arthritis Linked to Heart Attack Risk 2Health News:Lower levels of education are associated with increased risks of heart failure 2Health News:Lower levels of education are associated with increased risks of heart failure 3Health News:Lower levels of education are associated with increased risks of heart failure 4Health News:Trauma surgeon leads call to action for pediatric applied trauma research network 2Health News:Feeling included -- kids with disabilities have their say in landmark study 2Health News:Feeling included -- kids with disabilities have their say in landmark study 3Health News:Serotonin May Be the Key to SIDS 2Health News:Serotonin May Be the Key to SIDS 3Health News:Accurate diagnosis of prostate cancer with ultrasound 2Health News:Accurate diagnosis of prostate cancer with ultrasound 3
... Bulb Direct has been ... Internet since 1996, and we ... 100% satisfaction guarantee. Check out ... and see our discount light ...
With the Symphony family of Pacemakers, Ela presents the most advanced technology on the market. Symphony, lighter than a passport, will take your patients further, offering fast follow-up, using new...
With the Symphony family of Pacemakers, Ela presents the most advanced technology on the market. Symphony, lighter than a passport, will take your patients further, offering fast follow-up, using new...
.90mm (20G) guillotine cutting probe with 1.4mm (17G) removable irrigation sleeve...
Medicine Products: